Form D · Biotechnology

GeneCentric Therapeutics, Inc.

Durham, NC · CIK 0001529224

Offering snapshot reported Jun 20, 2025 · SEC filing

Reported sold
$2M
Offering amount: $5M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 4, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 20, 2025Initial$1,999,967No comparison9SEC filing
Sep 20, 2022Initial$2,500,000No comparison1SEC filing
Oct 7, 2021Initial$4,500,000No comparison1SEC filing
Jan 13, 2021Initial$1,200,000No comparison4SEC filing
Jan 5, 2017Initial$6,105,996No comparison4SEC filing
Jul 11, 2014Amendment$5,000,010$2,500,005vs Jul 2, 20134SEC filing
Jul 2, 2013Initial$2,500,005No comparison4SEC filing
Sep 16, 2011Initial$250,000No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-549421

Source: Form D, filed Jun 20, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Perou V. Charles Director, Executive
Don Hardison Director
David Neil Hayes Director, Executive
Myla Lai Goldman Director
Arnold Levine Director
Ellen Lubman Director
Michael Milburn Director, Executive
Charles Perou Director
Prasanth Reddy Director
Clay Thorp Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
100 Capitola Drive Suite 275
Durham, NC, 27713